

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/659,747	
			Filing Date	September 11, 2003	
			First Named Inventor	Alexander LEVITZKI et al	
			Group Art Unit	1618	
			Examiner Name	JONES, DAMERON LEVEST	
Sheet	2	Of	2	Attorney Docket Number	26682
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	10	Smaill et al. "Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)Quinazoline- and 4-(Phenylamino)Pyrido[3,2-d]Pyrimidine-6-Acrylamides Bearing Additional Solubilizing Functions", Journal of Medicinal Chemistry, 43: 1380-1397, 2000. Compound 18, 25-27, Table 1.			
	11	Smaill et al. "Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)Quiazoline and 4-(Phenylamino)Pyrido[d]Pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor", Journal of Medicinal Chemistry, 42: 1802-1815, 1999.			
	12	Mishani et al. "Carbon-11 Labeling of -Dimethylamino-But-2-Enoic Acid [4-(Phenylamino)-Quinazolin-6-Yl]-Amides, A New Class of EGFR Irreversible Inhibitors", Journal of Labelled Compounds and Radiopharmaceuticals, 46(S1): S2, 2003. Abstract.			
	13	Ortu et al. "Labeled EGFR-TK Irreversible Inhibitor (ML03) In Vitro and In Vivo Properties, Potential as Pet Biomarker for Cancer and Feasibility as Anticancer Drug", International Journal of Cancer, 101: 360-370, 2002. Conclusion, P.361, Col.1, § 1, Fig.1.			
	14	Johnström et al. "Synthesis of [Methoxy-11C]PD153035, A Selective EGF Receptor Tyrosine Kinase Inhibitor", Journal of Labelled Compounds and Radiopharmaceuticals, XLI: 623-629, 1998. P.627, Fig.3.			
	15	Mishani et al. "Novel Carbon-11 Labeled 4-Dimethylamino-But-2-Enoic Acid [4-(Phenylamino)-Quinazoline-6-Yl]-Amides: Potential PET Bioprobes for Molecular Imaging of EGFR-Positive Tumors", Nuclear Medicine and Biology, 31(4): 469-476, 2004. P.474, Col.2, § 4 - P.475, Figs.2, 3.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.